1. The CRO model is of great significance to the pharmaceutical industry. It is conducive to increasing the speed of new drug launches for pharmaceutical companies and reducing the management and research and development costs of pharmaceutical companies. 2. Cro concept stocks are more popular, as long as investors meet the requirements.

Can be purchased.

Among them, pharmaceutical cro companies provide technical services including new drug product development, data management, new drug application, as well as preclinical research and clinical trials, covering the entire process of new drug research and development.

Whether to enter the stock market, investors should make their own judgment based on their own investment goals and financial status. 3. In terms of market conditions, cro concept stocks are considered high-performance stocks, but the overall domestic market size is still relatively small.

Moreover, many stock companies are high-quality growth stocks in the pharmaceutical sector.

Note that stocks belonging to the GEM or the Science and Technology Innovation Board are relatively risky, and investors need to have strong resistance when buying them. 1. Contract Research Organization (CRO) originated in the United States in the early 1980s.

, it is an academic or commercial science that provides professional services in the research and development process of basic medicine and clinical medicine to pharmaceutical companies, medical institutions, small and medium-sized pharmaceutical and medical device R&D companies, and even various government funds through contracts.

mechanism.

2. For local CROs that focus on domestic pharmaceutical companies, China's pharmaceutical industry is relatively immature, has little demand for product innovation, and has a small research budget. CRO services are mostly focused on optimizing the synthesis route of compounds, drug registration trials, and post-drug administration in hospitals.

Phase IV clinical trials, etc., most do not require comprehensive services.

Local CROs must understand their core competitiveness and their own development model. They must understand what they can do to give full play to their strengths and do better than foreign companies.

3. With the development of science and technology, some large pharmaceutical companies engaged in drug research and development are facing the continuous emergence of new compounds and new technologies. When it is difficult to cope with the company's own capabilities alone, some laborious and time-consuming clinical tasks will be carried out.

Research work is outsourced, or technical support and services need to be provided from outside the enterprise.